TITAN PHARMACEUTICALS INC Logo

TITAN PHARMACEUTICALS INC

Develops a long-term drug delivery implant for treating chronic central nervous system disorders.

TTNP | US

Overview

Corporate Details

ISIN(s):
US8883146065
LEI:
Country:
United States of America
Address:
400 OYSTER POINT BLVD, 94080 SAN FRANCISCO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Titan Pharmaceuticals, Inc. is a development-stage biopharmaceutical company that develops proprietary therapeutics for the treatment of select chronic diseases. The company's core technology is its clinically proven ProNeura® platform, a long-term, continuous drug delivery system. This platform is designed to deliver stable, non-fluctuating levels of medication for periods of up to one year from a single subcutaneous implant. Titan's research and development activities are focused on exploring new therapeutic applications for the ProNeura platform, with a primary emphasis on treating central nervous system disorders. In late 2023, the company announced a merger with Black Titan Corporation.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all TITAN PHARMACEUTICALS INC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TITAN PHARMACEUTICALS INC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TITAN PHARMACEUTICALS INC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nxera Pharma Co., Ltd. Logo
Biopharma using SBDD tech to develop medicines for neurology and gastroenterology.
Japan
4565
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
ObsEva SA Logo
Developed novel therapeutics for women's reproductive health and pregnancy.
Switzerland
OBSN
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
OCULAR THERAPEUTIX, INC Logo
Develops hydrogel drug delivery therapies for eye diseases like wet AMD and glaucoma.
United States of America
OCUL
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
ODI Pharma AB Logo
Distributes pharmaceutical medicinal cannabis products across Eastern Europe, with a focus on Poland.
Sweden
ODI
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
Olema Pharmaceuticals, Inc. Logo
A clinical-stage biopharma developing targeted therapies for women's cancers, focusing on breast cancer.
United States of America
OLMA

Talk to a Data Expert

Have a question? We'll get back to you promptly.